Respiratory Syncytial Virus Exceeded SARS‐CoV‐2 and Influenza in Lower Respiratory Infection and Mortality Rates Among Patients With Hematologic Malignancies During the 2023–2024 Respiratory Virus Season
During the 2023-2024 RV season, the clinical impact of these viruses on patients with HMs remains significant, with higher morbidity and mortality from RSV, highlighting the persistent unmet need for better management strategies for RVIs in the post-pandemic era.
Authors
- Ying Jiang (ORCID: https://orcid.org/0000-0001-6269-0172)
- Fareed Khawaja (ORCID: https://orcid.org/0000-0003-4424-283X)
- Amy Spallone (ORCID: https://orcid.org/0000-0002-7513-6522)
- Tali Shafat (ORCID: https://orcid.org/0000-0001-6675-7362)
- Roy F. Chemaly (ORCID: https://orcid.org/0000-0002-0277-3088)
- Lior Nesher (ORCID: https://orcid.org/0000-0002-1230-0428)
- Jennifer Jackson (ORCID: https://orcid.org/0000-0001-5998-1999)
Institutions
- Ben-Gurion University of the Negev (IL)
- The University of Texas MD Anderson Cancer Center (US)
- European Society of Clinical Microbiology and Infectious Diseases (CH)
Publication Details
- Journal
- Transplant Infectious Disease
- Published
- 2025-10-08
- DOI
- https://doi.org/10.1111/tid.70113
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Texas MD Anderson Cancer Center